CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with JMT-108 for advanced malignant tumors.

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share in cash, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone, a small molecule for treating a rare, aggressive glioma that’s often found in children and young adults.

Sofinnova Partners raised a whopping €1.2 billion (US$1.26 billion) over the past year to invest in life sciences companies ranging from incubation to later-stage growth, and spanning biotech, med tech, industrial biotech and digital medicine.

Bioheng Therapeutics US LLC has obtained IND approval from the FDA for CTD-402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.

Tharimmune Inc. has applied its Epiclick multispecific antibody engineering platform to expand its pipeline. With Epiclick, the company can combine distinct antibody binding domains, including those derived from previously inaccessible and undruggable epitopes, in either small-format or full-length configurations to target hard-to-reach epitopes.

Combining the direct cytotoxic effects of antibody-drug conjugates (ADCs) with the immune-enhancing properties of immunostimulators represents a new therapeutic strategy that could not only eradicate tumor cells, but also reprogram the tumor microenvironment, leading to durable and systemic anticancer immunity. Using this new approach, researchers from Bioray Pharmaceutical Co. Ltd. developed and characterized of a new dual drug ADC (BiADC), named BR-113, designed to target human (h)Trop2.